Peer-influenced content. Sources you trust. No registration required. This is HCN.

Psychiatrist.comLumateperone for the Treatment of Schizophrenia: Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed

Lumateperone 42 mg/d is effective in the treatment of schizophrenia and has no clinically significant effects on body weight, metabolic variables, motor function, the ECG QT interval, or prolactin levels, with a likelihood to be helped or harmed (LHH) much greater than 1 when comparing therapeutic response to these tolerability/safety outcomes. When comparing therapeutic response versus a somnolence/sedation AE, lumateperone appears to be associated with somnolence/sedation, and LHH approaches 1. In indirect comparisons with other antipsychotics, this somnolence/sedation AE profile is not dissimilar; however, the absence of weight gain, glucose/lipid abnormalities, and akathisia, as well as the absence of prolactin elevations, distinguishes lumateperone.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form